A5007710082- Cancer Research and Treatments
- Gastric Cancer Management and Outcomes
- Cancer Mechanisms and Therapy
- Tryptophan and brain disorders
- Pancreatic and Hepatic Oncology Research
- Bipolar Disorder and Treatment
- Stress Responses and Cortisol
- Cancer therapeutics and mechanisms
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Biopolymer Synthesis and Applications
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Gut microbiota and health
- Biochemical and Molecular Research
- Forensic Toxicology and Drug Analysis
- HIV/AIDS drug development and treatment
- Child Nutrition and Feeding Issues
- Pancreatitis Pathology and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Gastroesophageal reflux and treatments
- Eating Disorders and Behaviors
- Poisoning and overdose treatments
- Monoclonal and Polyclonal Antibodies Research
- Pancreatic function and diabetes
- Cholinesterase and Neurodegenerative Diseases
Ipsen (France)
2020-2023
GlaxoSmithKline (France)
2013-2017
Institut Galien Paris-Saclay
2007
Hôpital Ambroise-Paré
2006
The long serum t1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. glycosylation thought not to influence FcRn binding and longevity in vivo. In this article, we demonstrate that hypersialylation asparagine 297 (N297) enhances persistence. This polarized achieved using a novel mutation, glutamate residue deletion at position 294 (Del) endows an up 9-fold increase lifespan. strongest impact was observed when Del...
The hybridization of hits, identified by complementary fragment and high throughput screens, enabled the discovery first series potent inhibitors mitochondrial branched-chain aminotransferase (BCATm) based on a 2-benzylamino-pyrazolo[1,5-a]pyrimidinone-3-carbonitrile template. Structure-guided growth rapid optimization potency with maintenance ligand efficiency, while focus physicochemical properties delivered compounds excellent pharmacokinetic exposure that proof concept experiment in...
Recently, we reported a novel role for KMO in the pathogenesis of acute pancreatitis (AP). A number inhibitors kynurenine 3-monooxygenase (KMO) have previously been described as potential treatments neurodegenerative conditions and particularly Huntington's disease. However, to date insufficient aqueous solubility relative their cellular potency be compatible with intravenous (iv) dosing route required AP. We identified optimized series high affinity favorable physicochemical properties. The...
AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel-sensing enzyme that activated in shortage of energy and suppressed its surfeit. AMPK activation stimulates fatty acid oxidation, enhances insulin sensitivity, alleviates hyperglycemia hyperlipidemia, inhibits proinflammatory changes. Thus, a well-received therapeutic target for type 2 diabetes other metabolic disorders. Here, we will report the discovery pyrrolopyridone derivatives as direct activators. We illustrate...
Liposomal irinotecan promotes controlled sustained release of (CPT-11), therefore, we hypothesize that the therapeutic index (quantitative measurement relative efficacy/safety ratio a drug) will be higher for liposomal than non-liposomal irinotecan. We compared indexes and in mice bearing subcutaneous patient-derived xenograft (PDX) pancreatic tumors under dosing regimens approximating clinical setting. Following preliminary drug sensitivity/antitumor activity analyses on three PDX tumor...
Abstract Gastric adenocarcinoma (GAC) is the third most common cause of cancer-related deaths worldwide. Combination chemotherapy remains standard treatment for advanced GAC. Liposomal irinotecan (nal-IRI) has improved pharmacokinetics (PK) and drug biodistribution compared with (IRI, CPT-11). Angiogenesis plays a crucial role in progression metastasis We evaluated antitumor efficacy nal-IRI combination novel antiangiogenic agents GAC mouse models. Animal survival studies were performed...
e16724 Background: Liposomal irinotecan (ONIVYDE) is approved with 5-fluorouracil/leucovorin for metastatic pancreatic ductal adenocarcinoma (PDAC) post progression on gemcitabine-based therapy. The liposomal formulation prolongs payload residence time in the circulation and tumor lesions, where local conversion to active metabolite SN-38 thought occur. effect of therapeutic index (TI) was assessed patient-derived xenograft PDAC models (IM-PAN-001 [untreated tumor] SA-PAN-077) severe...
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
<div>Abstract<p>Gastric adenocarcinoma (GAC) is the third most common cause of cancer-related deaths worldwide. Combination chemotherapy remains standard treatment for advanced GAC. Liposomal irinotecan (nal-IRI) has improved pharmacokinetics (PK) and drug biodistribution compared with (IRI, CPT-11). Angiogenesis plays a crucial role in progression metastasis We evaluated antitumor efficacy nal-IRI combination novel antiangiogenic agents GAC mouse models. Animal survival studies...
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
<div>Abstract<p>Gastric adenocarcinoma (GAC) is the third most common cause of cancer-related deaths worldwide. Combination chemotherapy remains standard treatment for advanced GAC. Liposomal irinotecan (nal-IRI) has improved pharmacokinetics (PK) and drug biodistribution compared with (IRI, CPT-11). Angiogenesis plays a crucial role in progression metastasis We evaluated antitumor efficacy nal-IRI combination novel antiangiogenic agents GAC mouse models. Animal survival studies...
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Supplementary Figure from Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
Abstract BACKGROUND: Gastric adenocarcinoma (GAC) remains the 3rd most common cause of cancer-related deaths worldwide. Systemic chemotherapy is commonly a fundamental treatment for metastatic GAC that usually leads to modest patient benefit, resulting in 5-year survival rate 31%. A liposomal formulation irinotecan (nal-IRI) has shown improved pharmacokinetic and drug biodistribution compared with free (IRI) preclinical studies. Angiogenesis plays crucial role progression metastasis GAC. We...